Karen R. Rabin, MD, PhD
Dr. Karen Rabin’s research focuses on the biology of acute lymphoblastic leukemia (ALL), with a particular interest in children with Down syndrome, including the molecular basis for leukemogenesis in these patients and the basis for their increased risk of treatment-related toxicities. Further study of this specific, genetically homogeneous patient population may generate insights that ultimately have broad applicability in improving our understanding of leukemogenesis and our development of improved treatments in leukemia.
Dr. Rabin also has research interests in molecular determinants associated with prognosis in childhood ALL, and identification of novel therapeutic targets. Dr. Rabin is currently the Children’s Oncology Group (COG) site PI for Baylor College of Medicine, Vice Chair of the COG ALL Cell Bank, Chair of the COG ALL Classification Study AALL08B1, and member of the High Risk ALL Study Committee AALL1131.